Synta Provides Clinical Updates

Synta Pharmaceuticals Corp.

today provided clinical updates and reported financial results for the second quarter ended June 30, 2013. Clinical Updates Our lead clinical candidate is ganetespib, a selective inhibitor of the Hsp90 chaperone protein, which is being evaluated in over 25 clinical trials that have enrolled over a thousand patients to date, including our GALAXY program in lung cancer and our ENCHANT program in breast cancer. The GALAXY program in lung cancer At the 2013 meeting of the American Society of Clinical Oncology (ASCO), investigators presented results from an interim analysis